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Coffee, a major dietary source of caffeine, is amongst the most widely consumed beverages in 
the world and has received considerable attention regarding health risks and benefits. We 
conducted a genome-wide(GW) meta-analysis of predominately regular-type coffee consumption 
(cups/day) among up to 91,462 coffee consumers of European ancestry with top single-
nucleotide polymorphisms (SNPs) followed-up in ~30,062 and 7,964, coffee consumers of 
European and African American ancestry, respectively. Studies from both stages were combined 
in a trans-ethnic meta-analysis. Confirmed loci were examined for putative functional and 
biological relevance. Eight loci, including six novel loci, met GW-significance (log10Bayes-
factor>5.64) with per allele effect sizes of 0.03-0.14 cups/day. Six are located in or near genes 
potentially involved in pharmacokinetics (ABCG2, AHR, POR, CYP1A2) and pharmacodynamics 
(BDNF, SLC6A4) of caffeine. Two map to GCKR and MLXIPL, genes related to metabolic traits 
but lacking known roles in coffee consumption. Enhancer and promoter histone marks populate 
the regions of many confirmed loci and several potential regulatory SNPs are highly correlated 
with the lead SNP of each. SNP alleles near GCKR, MLXIPL, BDNF and CYP1A2 that were 
associated with higher coffee consumption have previously been associated with smoking 
initiation, higher adiposity and fasting insulin and glucose but lower blood pressure and 
favorable lipid, inflammatory and liver enzyme profiles (P<5×10-8).Our genetic findings among 
European and African American adults reinforce the role of caffeine in mediating habitual coffee 
consumption and may point to molecular mechanisms underlying inter-individual variability in 
pharmacological and health effects of coffee. 
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INTRODUCTION 
Coffee is amongst the most widely consumed beverages in the world1. North American coffee 
drinkers typically consume ~2 cups per day while the norm is at least 4 cups in many European 
countries1. In prospective cohort studies, coffee consumption is consistently associated with 
lower risk of Parkinson’s disease, liver disease and type 2 diabetes2. However, the effects of 
coffee on cancer development, cardiovascular and birth outcomes and other health conditions 
remain controversial2. For most populations, coffee is the primary source of caffeine, a stimulant 
also present in other beverages, foods and medications1, 3. The fifth edition of the Diagnostic and 
Statistical Manual of Mental Disorders does not include a diagnosis of caffeine dependence or 
abuse due to a paucity of evidence but lists caffeine intoxication and withdrawal as Disorders4. 
Knowledge of factors contributing to coffee’s consumption and physiological effects may greatly 
advance the design and interpretation of population and clinical research on coffee and caffeine5. 
Genetic factors could be especially valuable as they offer ways to study the potential health 
effects of coffee via instrumental variables or gene-environment interactions5. Heritability 
estimates for coffee and caffeine use range between 43 and 58%6. Genome-wide association 
studies (GWAS) of habitual caffeine and coffee intake have identified variants near CYP1A2 and 
AHR7-9.  Cytochrome P450 (CYP)1A2 is responsible for ~95% of caffeine metabolism in 
humans and aryl hydrocarbon receptor (AHR) plays a regulatory role in basal and substrate-
induced expression of target genes, including CYP1A1 and CYP1A210, 11.  
To identify additional loci, we conducted a staged GW meta-analysis of coffee 
consumption including over 120,000 coffee consumers sourced from population-based studies of 
European and African American ancestry. 
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MATERIALS AND METHODS 
Study design and populations  
Supplementary Figure S1 depicts an overview of the current study. We performed a meta-
analysis of GWAS summary statistics from 28 population-based studies of European ancestry to 
detect single-nucleotide polymorphisms (SNPs) that are associated with coffee consumption. 
Top loci were followed-up in studies of European (13 studies) and African American (7 studies) 
ancestry and confirmed loci were explored in a single Pakistani population. Detailed information 
on study design, participant characteristics, genotyping and imputation for all contributing 
studies are provided in the Supplementary Information and Supplementary Tables S1-S6.  
 
Phenotype 
All phenotype data were previously collected via interviewer- or self-administered 
questionnaires (Supplementary Table S1). Our primary phenotype (‘phenotype 1’) was cups of 
predominately regular-type coffee consumed per day among coffee consumers. Coffee data 
collected categorically (e.g. 2-3 cups/day) was converted to cups/day by taking the median value 
of each category (e.g. 2.5 cups/day). A secondary analysis was performed comparing high to 
infrequent/non- coffee consumers (‘phenotype 2’). A subset of stage 1 studies collected 
information on decaffeinated coffee consumption; which was examined in follow-up analysis of 
the confirmed loci. 
 
Statistical analysis  
Each stage 1 (discovery) study performed GWA-testing for each phenotype across ~2.5 million 
genotyped or imputed autosomal SNPs (HapMap II, Centre d’Etude du Polymorphisme Humain 
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[CEU] reference), based on linear (cups/day, phenotype-1) or logistic (high vs. none/low, 
phenotype-2) regression under an additive genetic model. Analyses were adjusted for age, 
smoking status and, when applicable, sex, case-control status, study-site, family structure and/or 
study specific principal components of population substructure (Supplementary Table S7). SNPs 
with minor allele frequency (MAF) <0.02 or with low imputation quality scores were removed 
prior to meta-analysis (Supplementary Table S5). The GWAtoolbox (see Supplementary 
Information for URLs) was used for initial quality control. Plots of study (1/median standard 
error of effect size) vs. (square root of sample size) and MAFs were also viewed for outliers and 
these were addressed prior to the final meta-analysis.  
For both phenotypes, GW meta‐analysis was conducted using a fixed effects model and 
inverse‐variance weighting with a single genomic control (GC) correction as implemented in 
METAL12 and GWAMA13 (r>0.99 for correlation between METAL and GWAMA results). The 
phenotypic variance explained by additive SNP effects was estimated in the Women’s Genome 
Health Study (WGHS, n=15,987 with identity-by-state <0.025) using GCTA 14. Stage 1 
summary statistics were also subject to pathway analysis using MAGENTA15 (Supplementary 
Information).  
For regions achieving association P values <5×10-8  (7p21, 7q23.11, 11p13, 15q24) we 
performed conditional analysis using the summary statistics from the meta-analysis to test for the 
association of each SNP while conditioning on the top SNPs, with correlations between SNPs 
due to linkage disequilibrium (LD) estimated from the imputed genotype data from the 
Atherosclerosis Risk in Communities cohort16, a large and representative cohort of men and 
women of European ancestry. 
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Our approach to selecting SNPs for replication (stage 2) is described in Supplementary 
Information. Stage 2 meta-analyses were performed separately for European and African 
American populations, using the same statistical models and methods as described for stage 1, 
but without GC (Supplementary Information).  
Studies from all stages were included in an overall meta-analysis using Meta-ANalysis of 
TRans-ethnic Association studies (MANTRA)17; which adopts a Bayesian framework to 
combine results from different ethnic groups by taking advantage of the expected similarity in 
allelic effects between the most closely related populations. MANTRA was limited to SNPs 
selected for replication thus no GC was applied. A random effects analysis using GWAMA was 
performed in parallel to obtain effect estimates, which are not generated by MANTRA. The GW-
significance threshold of log10 BF >5.64 approximates a traditional GW P-value threshold of 
5×10-8 under general assumptions18, 19. Subgroup analysis and meta-regression were performed 
to investigate possible sources of between-study heterogeneity (Supplementary Information). 
Fine-mapping: To assess the improvement in fine-mapping resolution due to trans-ethnic meta-
analysis we applied the methods of Franceschini et al 17 to stage 1 and stage 2 (African 
Americans only) GW-summary level data (Supplementary Information).  
 
Potential SNP-function and biological and clinical inferences 
Details pertaining to follow-up of confirmed loci are provided in the Supplementary Information. 
Briefly, all confirmed index SNPs and their correlated proxies were examined for putative 
function using publicly available resources.  Bioinformatics and computational tools were used 
to systematically mine available knowledge and experimental databases to inform biological 
hypotheses underlying the link between loci and coffee consumption as well as connections 
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between loci. For these analyses all genes mapping to the confirmed regions were considered 
potential candidates. Finally, we searched the National Human Genome Research Institute 
GWAS catalogue20 and Metabolomics GWAS server 21 for all GW-significant associations with 
our confirmed coffee-SNPs. Complete GWAS summary data for coffee-implicated diseases or 
traits were additionally queried.  
RESULTS 
SNPs associated with coffee consumption 
Discovery stage 
Results from the discovery stage are summarized in Supplementary Figs S2-S5. Little evidence 
for genomic inflation (λ<1.07) was observed for either phenotype. The two analyses yielded 
similarly ranked loci and significant enrichment of ‘xenobiotic’ genes (MAGENTA’s 
FDR<0.006), suggesting no major difference in the genetic influence on coffee drinking 
initiation compared with the level of coffee consumption among coffee consumers at these loci. 
Overall, approximately 7.1% (standard error: 2%) of the variance in coffee cups consumed per 
day (phenotype-1) could be explained by additive and common SNP effects in the WGHS. 
Conditioning on the index SNPs of each region achieving association P values <5×10-8 
(7p21, 7q23.11, 11p13, 15q24) in the discovery stage provided little evidence for multiple 
independent variants (Supplementary Figure S6).  Only four of the SNPs on chromosome 7 were 
potentially independent and carried forward with other promising SNPs. 
Replication and trans-ethnic meta-analysis  
Forty-four SNPs spanning 33 genomic regions met significance criteria for candidate 
associations and were followed-up in stage 2 (Supplementary Tables S8-S13). Eight loci, 
including six novel, met our criteria for GW-significance (log10 BF>5.64) in a trans-ethnic meta-
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analysis of all discovery and replication studies (Table 1, Supplementary Tables S14-S16, 
Supplementary Figs S7 and S8).  Confirmed loci have effect sizes of 0.03-0.14 cups/day per 
allele and together explain ~1.3% of the phenotypic variance of coffee intake. We were 
underpowered to replicate these associations in a Pakistani population (Supplementary 
Information).  
 
Functional and biological inferences 
Enhancer (H3K4me1) and promoter (H3K4me3) histone marks densely populate many of these 
regions and several nonsynonymous and potential regulatory SNPs are highly correlated (r2>0.8) 
with the lead SNP and thus strong candidates for being a causal variant (Table 2, Supplementary 
Information, Supplementary Tables S17-S19). Candidate genes form a highly connected network 
of interactions, featuring discernible clusters of genes around BDNF and AHR (Figure 1, 
Supplementary Information, Supplementary Tables S20 and S21). At least one gene in each of 
the eight regions i) is highly expressed in brain, liver and/or taste buds, ii) results in phenotype 
abnormalities relevant to coffee consumption behavior when modified in mice, and iii) is 
differentially expressed in human hepatocytes when treated with high (7500 µM) but not low 
(1500 µM) doses of caffeine (Table 2, Supplementary Tables S22-S24).  
Additional genomic characterization of the top loci allows further biological inference as 
follows:  
i) Previously identified loci near AHR (7p21) and CYP1A2 (15q24) 
Consistent with previous reports in smaller samples7-9, the intergenic 7p21 and 15q24 loci near 
AHR and CYP1A1/CYP1A2 respectively remained the most prominent and highly heterogeneous 
loci associated with coffee consumption. The same index SNPs were identified in European and 
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African Americans suggesting they are robust HapMap proxies for causal variants in these two 
populations. Cohort-wide mean coffee consumption explained part of the heterogeneity in study 
results for both loci (Supplementary Table S25, Supplementary Information). The rs2472297 T 
and rs4410790 C alleles associated with increased coffee consumption have recently been 
associated with lower plasma caffeine levels 21 and shown to increase CYP1A2-mediated 
metabolism of olanzapine22.  The C allele of rs4410790 is also positively correlated with 
cerebellum AHR methylation, suggesting a novel role of Ahr in motor or learning pathways that 
may trigger coffee consumption. The most significant variants at 15q24 reside in the CYP1A1-
CYP1A2 bidirectional promoter where AHR response elements have been identified and shown 
to be important for transcriptional activation of both CYP1A1 and CYP1A223.  The rs2472297 T 
variant putatively weakens the binding of SP1, a co-activator in the Ahr-Arnt complex regulating 
CYP1 locus transcription24 and is also implicated in the expression of several neighboring genes. 
The latter observation, together with this region’s high LD and long range chromatin interactions 
(Supplementary Figure S9), suggests a regulatory network among these genes. 
ii) Novel loci at 7q11.23 (POR) and 4q22 (ABCG2) likely function in caffeine metabolism 
Variants at 7q11.23 (rs17685) and 4q22 (rs1481012) map to novel yet biologically plausible 
candidate genes involved in xenobiotic metabolism. rs17685 maps to the 3’UTR of POR, 
encoding P450 oxidoreductase which transfers electrons to all microsomal CYP450s enzymes25.  
The rs17685 A variant associated with higher coffee consumption is linked to increased POR 
expression and potentially weakens the DNA binding of several transcriptional regulatory 
proteins including BHLHE40, which inhibits POR expression26. The same SNP is in LD (CEU: 
r2=0.93) with POR*28 (rs1057868, Ala503Val), which is associated with differential CYP 
activity depending on the CYP isoform, substrate and experimental model used27. rs1481012 at 
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4q22 maps to ABCG2, encoding a xenobiotic efflux transporter. rs1481012 is in LD (CEU: 
r2=0.92) with rs2231142 (Gln141Lys), a functional variant at an evolutionarily constrained 
residue28. However, fine-mapping of this region on the basis of reduced LD in the African 
American sample limited an initial 189102 kb region to a credible span of 6249 kb 
(Supplementary Table S16), that excluded rs2231142.  
iii) Novel loci at 11p13 (BDNF) and 17q11.2 (‘SLC6A4’) likely mediate the positive reinforcing 
properties of coffee constituents  
The index SNP at 11p13 is the widely investigated missense mutation (rs6265, Val66Met) in 
BDNF (Supplementary Table S26). Brain-derived neurotrophin factor (BDNF) modulates the 
activity of serotonin, dopamine and glutamate, neurotransmitters involved in mood-related 
circuits and plays a key role in memory and learning29. The Met66 allele impairs neuronal 
activity-dependent BDNF secretion30 and thus may attenuate the rewarding effects of coffee and, 
in turn, motivation to consume coffee. The increasingly recognized roles of BDNF in the 
chemosensory system and conditioned taste preferences may also be relevant31. The index SNP 
(rs9902453) at 17q11.2 maps to the EFCAB5 gene and is in LD (CEU: r2>0.8) with SNPs that 
alter regulatory motifs for AhR32 in the neighboring gene NSRP1, but neither gene is an obvious 
candidate for coffee consumption. Upstream of rs9902453 lies a possibly stronger candidate: 
SLC6A4 encoding the serotonin transporter. Serotonergic neurotransmission affects a wide range 
of behaviors including sensory processing and food-intake33.  
iv) Novel loci at 2p24 (GCKR) and 17q11.2 (MLXIPL) 
Variants at 2p24 (rs1260326) and 7q11.23 (rs7800944) map to GCKR and MLXIPL, 
respectively. The former has been associated with plasma glucose and multiple metabolic traits 
and the latter with plasma triglycerides (Table 3, Supplementary Table S27). Adjustment of 
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regression models for plasma lipids in the Women’s Genome Health Study (WGHS, n~17,000) 
and plasma glucose in TwinGene (n~8,800) did not significantly change the relationship between 
SNPs at these two loci and coffee consumption (P>0.48, Supplementary Tables S28 and S29). 
The rs1260326 T allele encodes a nonsynonymous change in the encoded, glucokinase 
regulatory protein (GKRP) leading to increased hepatic glucokinase activity34. GKRP and 
glucokinase may also cooperatively function in the glucose-sensing process of the brain35 that 
may, in turn, influence central pathways responding to coffee constituents. A direct link between 
MLXIPL and coffee consumption remains unclear, except for the interactions with other 
candidate genes (Figure 1). Experimental evidence and results from formal prioritization 
analyses also warrants consideration of other candidates in these regions (Table 2, Figure 1, 
Supplementary Tables S23, S26, S30, S31). For example, in the frontal cortex, the rs1260326 
allele positively associated with coffee consumption correlates with lower methylation of 
PPM1G; a putative regulatory target for AhR and binding target for PPP1R1B, which mediates 
psychostimulant effects of caffeine36.  
 
Pleiotropy and clinical inferences 
None of the eight loci was significantly associated with caffeine taste-intensity (P>0.02) or 
caffeine-induced insomnia (P>0.08), according to previously published GWAS of these traits 37-
39. SNPs near AHR associated with higher coffee consumption were also significantly associated 
with higher decaffeinated coffee consumption (~0.05 cups/day,  P<0.0004, n=24,426); perhaps a 
result of Pavlovian conditioning among individuals moderating their intake of regular coffee or 
the small amounts of caffeine in decaffeinated coffee1. 
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Across phenotypes in the GWAS catalog20, the alleles leading to higher coffee 
consumption at 2p24, 4q22, 7q11.23, 11p13 and 15q24 have been associated with one or more of 
the following: smoking initiation, higher adiposity and fasting insulin and glucose but lower 
blood pressure and favorable lipid, inflammatory and liver enzyme profiles (P<5×10-8, Table 3, 
Supplementary Table S27). Focused on metabolic, neurologic and psychiatric traits for which 
coffee has been implicated (Table 3, Supplementary Table S32), there were additional sub-GW 
significant associations in published GWAS. Variants associated with higher coffee consumption 
increased adiposity (rs1481012, P=4.85×10-3), birth weight (rs7800944, P=2.10×10-3), plasma 
high-density lipoprotein (HDL, rs7800944, P=2.24×10-3), risk of Parkinson’s disease 
(rs1481012, P=7.11×10-3), reduced blood pressure (rs6265, P=6.58×10-4; rs2472297, P<6.80×10-
5 and rs9902453, P=6.05×10-3), HDL (rs6968554, P=1.18×10-3), risk of major depressive 
disorder (rs17685, P=6.98×10-3) and bipolar disorder (rs1260326, P=2.31×10-3). Associations 
with adiposity, birth weight, blood pressure, HDL and bipolar disorder remain significant after 
correcting for the number of SNPs tested.   
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DISCUSSION 
Coffee’s widespread popularity and availability has fostered public health concerns of the 
potential health consequences of regular coffee consumption. Findings from epidemiological 
studies of coffee consumption and certain health conditions remain controversial2. Knowledge of 
genetic factors contributing to coffee’s consumption and physiological effects may inform the 
design and interpretation of population and clinical research on coffee5. In the current report, we 
present results of the largest GWAS of coffee intake to-date and the first to include populations 
of African American ancestry. In addition to confirming associations with AHR and CYP1A2, we 
have identified six new loci, not previously implicated in coffee drinking behavior.  
Our findings highlight an important role of the pharmacokinetic and pharmacodynamic 
properties of the caffeine component of coffee underlying a genetic propensity to consume the 
beverage. Loci near BDNF and SLC6A4 potentially impact consumption behavior by modulating 
the acute behavioral and reinforcing properties of caffeine. Others near AHR, CYP1A2, POR, and 
ABCG2 act indirectly by altering the metabolism of caffeine and thus the physiological levels of 
this stimulant. The current study is the first to link GCKR and MLXIPL variation to a behavioral 
trait. The nonsynonymous rs1260326 SNP in GCKR has been a GW-signal for various metabolic 
traits particularly those reflecting glucose-homeostasis (Table 3).  GCKR variation may impact 
the glucose-sensing process of the brain35 that may, in turn, influence central pathways 
responding to coffee constituents. mQTL and binding motif analysis suggests PPM1G may be 
another candidate underlying the association between rs1260326 and coffee consumption. 
Variants near MLXIPL have also topped the list of variants associated with plasma triglycerides 
(Table 3), but their link to coffee consumption remains unclear.  Future studies on the potential 
pleiotropic effects of these two loci are clearly warranted. Interestingly, several candidate genes 
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implicated in coffee consumption behavior, but not confirmed in our GWAS, interact with one or 
more of the eight confirmed loci (Figure 1). While these findings are encouraging for ongoing 
efforts they also emphasize the need to study sets or pathways of genes in the future. 
Specific SNPs associated with higher coffee consumption have previously been 
associated with smoking initiation, higher adiposity and fasting insulin and glucose but lower 
blood pressure and favorable lipid, inflammatory and liver enzyme profiles. Whether these 
relationships reflect pleiotropy, confounding, or offer insight to the potential causal role coffee 
plays in these traits merits further investigation. Future research, particularly Mendelian 
Randomization and gene-coffee interaction studies, will need to consider the direct and indirect 
roles that each SNP has in altering coffee drinking behavior as well as the potential for 
interactions between loci (Figure 1). The heterogeneous effects specific to AHR- and CYP1A2-
coffee associations point to SNP-specific interactions with the environment or population 
characteristics that might also warrant consideration (Supplementary Information).  
The strong cultural influences on norms of coffee drinking may have reduced our power 
for loci discovery. This might, in part, underlie our lack of replication in a Pakistani population, 
wherein coffee consumption is extremely rare. Methodological limitations specific to our 
approach may also have reduced our power for loci discovery or precision in estimating effect 
sizes (Supplementary Information). For example, some studies collected coffee data in categories 
of cups/day (e.g. 2-3 cups/day) rendering a less precise record of intake as well as a non-
Gaussian distributed trait for analysis. The precise chemical composition of different coffee 
preparations is also not captured by standard FFQs and is likely to vary within and between 
populations. Nevertheless, the eight loci together explain ~1.3% of the phenotypic variance, a 
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value at least as great as that reported for smoking behavior and alcohol consumption which are 
subject to similar limitations in GWAS40, 41.  
 In conclusion, our results support the hypothesis that metabolic and neurological 
mechanisms of caffeine contribute to coffee consumption habits. Individuals adapt their coffee 
consumption habits to balance perceived negative and reinforcing symptoms that are affected by 
genetic variation. Genetic control of this potential ‘titrating’ behavior would incidentally govern 
exposure to other potentially ‘bioactive’ constituents of coffee that may be related to the health 
effects of coffee or other sources of caffeine.   Thus, our findings may point to molecular 
mechanisms underlying inter-individual variability in pharmacological and health effects of 
coffee and caffeine.  
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(IPDGC) are as follows: Michael A Nalls (Laboratory of Neurogenetics, National Institute on 
Aging, National Institutes of Health, Bethesda, MD, USA), Vincent Plagnol (UCL Genetics 
Institute, London, UK), Dena G Hernandez (Laboratory of Neurogenetics, National Institute on 
Aging; and Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK), 
Manu Sharma (Department for Neurodegenerative Diseases, Hertie Institute for Clinical Brain 
Research, University of Tübingen, and DZNE, German Center for Neurodegenerative Diseases, 
Tübingen, Germany), Una-Marie Sheerin (Department of Molecular Neuroscience, UCL 
Institute of Neurology), Mohamad Saad (INSERM U563, CPTP, Toulouse, France; and Paul 
Sabatier University, Toulouse, France), Javier Simón-Sánchez (Department of Clinical Genetics, 
Section of Medical Genomics, VU University Medical Centre, Amsterdam, Netherlands), 
Claudia Schulte (Department for Neurodegenerative Diseases, Hertie Institute for Clinical Brain 
Research), Suzanne Lesage (INSERM, UMR_S975 [ formerly UMR_S679], Paris, France; 
Université Pierre et Marie Curie-Paris, Centre de Recherche de l’Institut du Cerveau et de la 
Moelle épinière, Paris, France; and CNRS, Paris, France), Sigurlaug Sveinbjörnsdóttir 
(Department of Neurology, Landspítali University Hospital, Reykjavík, Iceland; Department of 
Neurology, MEHT Broomfield Hospital, Chelmsford, Essex, UK; and Queen Mary College, 
University of London, London, UK), Sampath Arepalli (Laboratory of Neurogenetics, National 
Institute on Aging), Roger Barker (Department of Neurology, Addenbrooke’s Hospital, 
University of Cambridge, Cambridge, UK), Yoav Ben-Shlomo (School of Social and 
Community Medicine, University of Bristol), Henk W Berendse (Department of Neurology and 
Alzheimer Center, VU University Medical Center), Daniela Berg (Department for 
Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research and DZNE, German 
Center for Neurodegenerative diseases), Kailash Bhatia (Department of Motor Neuroscience, 
UCL Institute of Neurology), Rob M A de Bie (Department of Neurology, Academic Medical 
Center, University of Amsterdam, Amsterdam, Netherlands), Alessandro Biffi (Center for 
Human Genetic Research and Department of Neurology, Massachusetts General Hospital, 
Boston, MA, USA; and Program in Medical and Population Genetics, Broad Institute, 
Cambridge, MA, USA), Bas Bloem (Department of Neurology, Radboud University Nijmegen 
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Medical Centre, Nijmegen, Netherlands), Zoltan Bochdanovits (Department of Clinical Genetics, 
Section of Medical Genomics, VU University Medical Centre), Michael Bonin (Department of 
Medical Genetics, Institute of Human Genetics, University of Tübingen, Tübingen, Germany), 
Jose M Bras (Department of Molecular Neuroscience, UCL Institute of Neurology), Kathrin 
Brockmann (Department for Neurodegenerative Diseases, Hertie Institute for Clinical Brain 
Research and DZNE, German Center for Neurodegenerative diseases), Janet Brooks (Laboratory 
of Neurogenetics, National Institute on Aging), David J Burn (Newcastle University Clinical 
Ageing Research Unit, Campus for Ageing and Vitality, Newcastle upon Tyne, UK), Gavin 
Charlesworth (Department of Molecular Neuroscience, UCL Institute of Neurology), Honglei 
Chen (Epidemiology Branch, National Institute of Environmental Health Sciences, National 
Institutes of Health, NC, USA), Patrick F Chinnery (Neurology M4104, The Medical School, 
Framlington Place, Newcastle upon Tyne, UK), Sean Chong (Laboratory of Neurogenetics, 
National Institute on Aging), Carl E Clarke (School of Clinical and Experimental Medicine, 
University of Birmingham, Birmingham, UK; and Department of Neurology, City Hospital, 
Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, UK), Mark R Cookson 
(Laboratory of Neurogenetics, National Institute on Aging), J Mark Cooper (Department of 
Clinical Neurosciences, UCL Institute of Neurology), Jean Christophe Corvol (INSERM, 
UMR_S975; Université Pierre et Marie Curie-Paris; CNRS; and INSERM CIC-9503, Hôpital 
Pitié-Salpêtrière, Paris, France), Carl Counsell (University of Aberdeen, Division of Applied 
Health Sciences, Population Health Section, Aberdeen, UK), Philippe Damier (CHU Nantes, 
CIC0004, Service de Neurologie, Nantes, France), Jean-François Dartigues (INSERM U897, 
Université Victor Segalen, Bordeaux, France), Panos Deloukas (Wellcome Trust Sanger 
Institute, Wellcome Trust Genome Campus, Cambridge, UK), Günther Deuschl (Klinik für 
Neurologie, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Christian-Albrechts-
Universität Kiel, Kiel, Germany), David T Dexter (Parkinson’s Disease Research Group, Faculty 
of Medicine, Imperial College London, London, UK), Karin D van Dijk (Department of 
Neurology and Alzheimer Center, VU University Medical Center), Allissa Dillman (Laboratory 
of Neurogenetics, National Institute on Aging), Frank Durif (Service de Neurologie, Hôpital 
Gabriel Montpied, Clermont-Ferrand, France), Alexandra Dürr (INSERM, UMR_S975; 
Université Pierre et Marie Curie-Paris; CNRS; and AP-HP, Pitié-Salpêtrière Hospital), Sarah 
Edkins (Wellcome Trust Sanger Institute), Jonathan R Evans (Cambridge Centre for Brain 
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Repair, Cambridge, UK), Thomas Foltynie (UCL Institute of Neurology), Jing Dong 
(Epidemiology Branch, National Institute of Environmental Health Sciences), Michelle Gardner 
(Department of Molecular Neuroscience, UCL Institute of Neurology), J Raphael Gibbs 
(Laboratory of Neurogenetics, National Institute on Aging; and Department of Molecular 
Neuroscience, UCL Institute of Neurology), Alison Goate (Department of Psychiatry, 
Department of Neurology, Washington University School of Medicine, MI, USA), Emma Gray 
(Wellcome Trust Sanger Institute), Rita Guerreiro (Department of Molecular Neuroscience, UCL 
Institute of Neurology), Clare Harris (University of Aberdeen), Jacobus J van Hilten 
(Department of Neurology, Leiden University Medical Center, Leiden, Netherlands), Albert 
Hofman (Department of Epidemiology, Erasmus University Medical Center, Rotterdam, 
Netherlands), Albert Hollenbeck (AARP, Washington DC, USA), Janice Holton (Queen Square 
Brain Bank for Neurological Disorders, UCL Institute of Neurology), Michele Hu (Department 
of Clinical Neurology, John Radcliffe Hospital, Oxford, UK), Xuemei Huang (Departments of 
Neurology, Radiology, Neurosurgery, Pharmacology, Kinesiology, and Bioengineering, 
Pennsylvania State University– Milton S Hershey Medical Center, Hershey, PA, USA), Isabel 
Wurster (Department for Neurodegenerative Diseases, Hertie Institute for Clinical Brain 
Research and German Center for Neurodegenerative diseases), Walter Mätzler (Department for 
Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research and German Center for 
Neurodegenerative diseases), Gavin Hudson (Neurology M4104, The Medical School, 
Newcastle upon Tyne, UK), Sarah E Hunt (Wellcome Trust Sanger Institute), Johanna 
Huttenlocher (deCODE genetics), Thomas Illig (Institute of Epidemiology, Helmholtz Zentrum 
München, German Research Centre for Environmental Health, Neuherberg, Germany), Pálmi V 
Jónsson (Department of Geriatrics, Landspítali University Hospital, Reykjavík, Iceland), Jean-
Charles Lambert (INSERM U744, Lille, France; and Institut Pasteur de Lille, Université de Lille 
Nord, Lille, France), Cordelia Langford (Cambridge Centre for Brain Repair), Andrew Lees 
(Queen Square Brain Bank for Neurological Disorders), Peter Lichtner (Institute of Human 
Genetics, Helmholtz Zentrum München, German Research Centre for Environmental Health, 
Neuherberg, Germany), Patricia Limousin (Institute of Neurology, Sobell Department, Unit of 
Functional Neurosurgery, London, UK), Grisel Lopez (Section on Molecular Neurogenetics, 
Medical Genetics Branch, NHGRI, National Institutes of Health), Delia Lorenz (Klinik für 
Neurologie, Universitätsklinikum Schleswig-Holstein), Alisdair McNeill (Department of Clinical 
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Neurosciences, UCL Institute of Neurology), Catriona Moorby (School of Clinical and 
Experimental Medicine, University of Birmingham), Matthew Moore (Laboratory of 
Neurogenetics, National Institute on Aging), Huw R Morris (MRC Centre for Neuropsychiatric 
Genetics and Genomics, Cardiff University School of Medicine, Cardiff, UK), Karen E Morrison 
(School of Clinical and Experimental Medicine, University of Birmingham; and Neurosciences 
Department, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation 
Trust, Birmingham, UK), Ese Mudanohwo (Neurogenetics Unit, UCL Institute of Neurology and 
National Hospital for Neurology and Neurosurgery), Sean S O’Sullivan (Queen Square Brain 
Bank for Neurological Disorders), Justin Pearson (MRC Centre for Neuropsychiatric Genetics 
and Genomics), Joel S Perlmutter (Department of Neurology, Radiology, and Neurobiology at 
Washington University, St Louis), Hjörvar Pétursson (deCODE genetics; and Department of 
Medical Genetics, Institute of Human Genetics, University of Tübingen), Pierre Pollak (Service 
de Neurologie, CHU de Grenoble, Grenoble, France), Bart Post (Department of Neurology, 
Radboud University Nijmegen Medical Centre), Simon Potter (Wellcome Trust Sanger Institute), 
Bernard Ravina (Translational Neurology, Biogen Idec, MA, USA), Tamas Revesz (Queen 
Square Brain Bank for Neurological Disorders), Olaf Riess (Department of Medical Genetics, 
Institute of Human Genetics, University of Tübingen), Fernando Rivadeneira (Departments of 
Epidemiology and Internal Medicine, Erasmus University Medical Center), Patrizia Rizzu 
(Department of Clinical Genetics, Section of Medical Genomics, VU University Medical 
Centre), Mina Ryten (Department of Molecular Neuroscience, UCL Institute of Neurology), 
Stephen Sawcer (University of Cambridge, Department of Clinical Neurosciences, 
Addenbrooke’s hospital, Cambridge, UK), Anthony Schapira (Department of Clinical 
Neurosciences, UCL Institute of Neurology), Hans Scheffer (Department of Human Genetics, 
Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands), Karen Shaw (Queen 
Square Brain Bank for Neurological Disorders), Ira Shoulson (Department of Neurology, 
University of Rochester, Rochester, NY, USA), Ellen Sidransky (Section on Molecular 
Neurogenetics, Medical Genetics Branch, NHGRI), Colin Smith (Department of Pathology, 
University of Edinburgh, Edinburgh, UK), Chris C A Spencer (Wellcome Trust Centre for 
Human Genetics, Oxford, UK), Hreinn Stefánsson (deCODE genetics), Francesco Bettella 
(deCODE genetics), Joanna D Stockton (School of Clinical and Experimental Medicine), Amy 
Strange (Wellcome Trust Centre for Human Genetics), Kevin Talbot (University of Oxford, 
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Department of Clinical Neurology, John Radcliffe Hospital, Oxford, UK), Carlie M Tanner 
(Clinical Research Department, The Parkinson’s Institute and Clinical Center, Sunnyvale, CA, 
USA), Avazeh Tashakkori-Ghanbaria (Wellcome Trust Sanger Institute), François Tison 
(Service de Neurologie, Hôpital Haut-Lévêque, Pessac, France), Daniah Trabzuni (Department 
of Molecular Neuroscience, UCL Institute of Neurology), Bryan J Traynor (Laboratory of 
Neurogenetics, National Institute on Aging), André G Uitterlinden (Departments of 
Epidemiology and Internal Medicine, Erasmus University Medical Center), Daan Velseboer 
(Department of Neurology, Academic Medical Center), Marie Vidailhet (INSERM, UMR_S975, 
Université Pierre et Marie Curie-Paris, CNRS, UMR 7225), Robert Walker (Department of 
Pathology, University of Edinburgh), Bart van de Warrenburg (Department of Neurology, 
Radboud University Nijmegen Medical Centre), Mirdhu Wickremaratchi (Department of 
Neurology, Cardiff University, Cardiff, UK), Nigel Williams (MRC Centre for Neuropsychiatric 
Genetics and Genomics), Caroline H Williams-Gray (Department of Neurology, Addenbrooke’s 
Hospital), Sophie Winder-Rhodes (Department of Psychiatry and Medical Research Council and 
Wellcome Trust Behavioural and Clinical Neurosciences Institute, University of Cambridge), 
Kári Stefánsson (deCODE genetics), Maria Martinez (INSERM UMR 1043; and Paul Sabatier 
University), Nicholas W Wood (UCL Genetics Institute; and Department of Molecular 
Neuroscience, UCL Institute of Neurology), John Hardy (Department of Molecular 
Neuroscience, UCL Institute of Neurology), Peter Heutink (Department of Clinical Genetics, 
Section of Medical Genomics, VU University Medical Centre), Alexis Brice (INSERM, 
UMR_S975, Université Pierre et Marie Curie-Paris, CNRS, UMR 7225, AP-HP, Pitié-
Salpêtrière Hospital), Thomas Gasser (Department for Neurodegenerative Diseases, Hertie 
Institute for Clinical Brain Research, and DZNE, German Center for Neurodegenerative 
Diseases), Andrew B Singleton (Laboratory of Neurogenetics, National Institute on Aging). 
The members and affiliations of the North American Brain Expression Consortium (NABEC) are 
as follows: Andrew Singleton (Laboratory of Neurogenetics, National Institute on Aging, 
National Institutes of Health, Bethesda, MD, USA); Mark Cookson (Laboratory of 
Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA); 
J. Raphael Gibbs (Laboratory of Neurogenetics, National Institute on Aging, National Institutes 
of Health, Bethesda, MD, USA and Reta Lila Weston Institute and Department of Molecular 
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Neuroscience, UCL Institute of Neurology, Queen Square, London WC1N 3BG, UK); Dena 
Hernandez (Laboratory of Neurogenetics, National Institute on Aging, National Institutes of 
Health, Bethesda, MD, USA and Reta Lila Weston Institute and Department of Molecular 
Neuroscience, UCL Institute of Neurology, Queen Square, London WC1N 3BG, UK); Allissa 
Dillman (Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, 
Bethesda, MD, USA and Department of Neuroscience, Karolinska Institutet, 171 77 Stockholm, 
Sweden); Michael Nalls (Laboratory of Neurogenetics, National Institute on Aging, National 
Institutes of Health, Bethesda, MD, USA) Alan Zonderman (Research Resources Branch, 
National Institute on Aging, National Institutes of Health, Bethesda, MD, USA); Sampath 
Arepalli (Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, 
Bethesda, MD, USA); Luigi Ferrucci (Clinical Research Branch, National Institute on Aging, 
Baltimore, MD, USA); Robert Johnson (NICHD Brain and Tissue Bank for Developmental 
Disorders, University of Maryland Medical School, Baltimore, Maryland 21201, USA); Dan 
Longo (Lymphocyte Cell Biology Unit, Laboratory of Immunology, National Institute on Aging, 
National Institutes of Health, Baltimore, MD, USA); Richard O'Brien (Brain Resource Center, 
Johns Hopkins University, Baltimore, MD, USA); Bryan Traynor (Laboratory of Neurogenetics, 
National Institute on Aging, National Institutes of Health, Bethesda, MD, USA); Juan Troncoso 
(Brain Resource Center, Johns Hopkins University, Baltimore, MD, USA); Marcel van der Brug 
(Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, 
Bethesda, MD, USA and ITGR Biomarker Discovery Group, Genentech, South San Francisco, 
CA, USA); Ronald Zielke (NICHD Brain and Tissue Bank for Developmental Disorders, 
University of Maryland Medical School, Baltimore, Maryland 21201, USA). 
 
The members and affiliations of the United Kingdom Brain Expression Consortium are as 
follows (UKBEC): John Hardy (Reta Lila Weston Institute and Department of Molecular 
Neuroscience, UCL Institute of Neurology, Queen Square, London WC1N 3BG, UK); Michael 
Weale (Department of Medical and Molecular Genetics, King’s College London, 8th Floor, 
Tower Wing, Guy¹s Hospital, London SE1 9RT, UK); Mina Ryten (Reta Lila Weston Institute 
and Department of Molecular Neuroscience, UCL Institute of Neurology, Queen Square, London 
WC1N 3BG, UK); Adaikalavan Ramasamy (Department of Medical and Molecular Genetics, 
King’s College London, 8th Floor, Tower Wing, Guy’s Hospital, London SE1 9RT, UK and 
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Reta Lila Weston Institute and Department of Molecular Neuroscience, UCL Institute of 
Neurology, Queen Square, London WC1N 3BG, UK); Daniah Trabzuni (Reta Lila Weston 
Institute and Department of Molecular Neuroscience, UCL Institute of Neurology, Queen 
Square, London WC1N 3BG, UK and Department of Genetics, King Faisal Specialist Hospital 
and Research Centre, PO Box 3354, Riyadh 11211, Saudi Arabia); Colin Smith (Department of 
Neuropathology, MRC Sudden Death Brain Bank Project, University of Edinburgh, Wilkie 
Building, Teviot Place, Edinburgh EH8 9AG); Robert Walker (Department of Neuropathology, 
MRC Sudden Death Brain Bank Project, University of Edinburgh, Wilkie Building, Teviot 
Place, Edinburgh EH8 9AG).
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Figure Legends 
 
Figure 1.  Network describing direct interactions between candidate genes of confirmed loci.  
Relationships were retrieved from databases of transcription regulation and protein-protein 
interaction experiments (Supplementary Table S21). Genes are represented as nodes that are 
colored according to locus. Candidate genes for loci identified in the current study were 
supplemented with known candidate genes related to caffeine pharmacology (grey nodes). Edges 
indicate known interactions.
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Table 1. SNPs associated with cups of coffee consumed per day among coffee consumers 
Locus Index SNPa Closest Gene EA/ 
NEA 
EAF 
EUR/AA 
Stage 1b 
EUR 
n ≤ 91,462 
Stage 2 b Trans-Ethnic  
Meta-Analysisc EUR 
n ≤ 30,062 
AA 
n ≤ 7,964 
β (SE) P β (SE) P β (SE) P β (SE) Log10BF Post  
Prob 
n 
2p24 rs1260326 GCKR T/C .41/.17 -0.04 (0.01)  1.06 ×10-07 -0.03 (0.01) 0.02 -0.01 (0.03) 0.77 -0.04 (0.01) 6.48 0.07 129,417 
4q22 rs1481012 ABCG2 A/G .89/.95 0.06 (0.01) 1.13 ×10-06 0.03 (0.02) 0.11 0.16 (0.05) 1.27 ×10-03 0.06 (0.01) 6.08 0.23 126,019 
7p21 rs4410790 
rs6968554 
AHR T/C 
A/G 
.37/.52 
.39/.33 
-0.14 (0.01) 
-0.13 (0.01) 
1.48 ×10-57 
2.54 ×10-57 
-0.05 (0.01) 
-0.07 (0.01) 
1.66 ×10-04 
2.78 ×10-10 
-0.09 (0.02) 
-0.05 (0.02) 
2.37 ×10-06 
0.02 
-0.10 (0.01) 
-0.10 (0.01) 
58.87 
69.69 
0.96 
1.00 
116,674 
124,849 
7q11.23 rs7800944 MLXIPL T/C .72/.67 -0.05 (0.01) 7.82 ×10-09 -0.06 (0.02) 4.20 ×10-04 -0.02 (0.02) 0.37 -0.05 (0.01) 8.83 0.09 116,417 
7q11.23 rs17685 POR A/G .29/.19 0.07 (0.01) 9.06 ×10-14 0.05 (0.01) 1.01 ×10-03 0.07 (0.03) 7.55 ×10-03 0.07 (0.01) 15.12 0.08 115,465 
11p13 rs6265 BDNF T/C .19/.07 -0.05 (0.01) 3.40 ×10-07 -0.03 (0.01) 0.07 -0.05 (0.04) 0.25 -0.04 (0.01) 5.76 0.10 127,828 
15q24 rs2470893 
rs2472297 
CYP1A1,  
CYP1A2 
T/C 
T/C 
.31/.06 
.24/.06 
0.12 (0.01) 
0.15 (0.01) 
6.89 ×10-44 
6.45 ×10-47 
0.09 (0.01) 
0.11 (0.01) 
9.92 ×10-11 
3.26 ×10-16 
0.20 (0.07) 
0.19 (0.05) 
4.23 ×10-03 
8.62 ×10-05 
0.12 (0.01) 
0.14 (0.01) 
57.79 
62.77 
1.00 
0.97 
113,273 
116,272 
17q11.2 rs9902453 EFCAB5 A/G .54/.80 -0.04 (0.01) 2.26 ×10-06 -0.03 (0.01) 9.13 ×10-03 -0.04 (0.03) 0.17 -0.03 (0.01) 6.29 0.05 126,819 
Abbreviations: EA, effect allele; NEA, non-effect allele; EAF, effect allele frequency; EUR, European ancestry; AA, African American ancestry; SE, standard error; BF, Bayes-
factor, Post Prob, posterior probability 
aGenic SNPs are in bold-face.  
bEffect coefficients (SE), representing cups/day per effect allele,  and corresponding P-values from stage 1 fixed-effects meta-analysis (columns 6, 7) and stage 2 fixed-effects 
meta-analyses (columns 8-11).  
cEffect coefficients (SE), representing cups/day per effect allele, from random-effects meta-analysis of all stage 1 and stage 2 studies (column 12). Log10BF (column 13) and 
corresponding posterior probabilities (column 14) from trans-ethnic meta-analysis of all stage 1 and stage 2 studies. A posterior probability > 0.5 suggests heterogeneity in allelic 
effects.
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Table 2. Potential function of loci associated with coffee consumptiona 
Locus Gene expression 
response to 
caffeineb 
Lead-SNP, 
allele ↑ 
coffee  
consumptionc 
Non-Syn 
SNPs in 
LDd 
CRe DNAsef Proteins 
Boundg 
Histone 
Marksh 
Motifs changedi eQTLj mQTLk 
2p24 GCKR, CCDC121, 
FNDC4, ZNF513, 
SNX17, PPM1G, 
GPN1, SUPT7L, 
MPV17, SLC4A1AP, 
PREB, ATRAID, 
GTF3C2  
rs1260326, C 
   
Leu446Pro    enhancer 
 
NRSF EIF2B4, 
SNX17,  
NRBP1 
KRTCAP3, 
PPM1G 
4q22 ABCG2, SPP1  rs1481012, A     enhancer AIRE, Zfp105   
7p21 AHR rs4410790, C 
rs6968554, G 
     Cdx2, DMRT3, E4BP4, Foxa, GR, 
Hoxa10, Hoxa9, Hoxb13, Hoxb9, 
Hoxc9, Hoxd10, Myc, p300, TR4 
 AHR 
7q11.23 MLXIPL, BCL7B, 
DNAJC30, TBL2, 
WBSCR22 
rs7800944, C     promoter  
enhancer  
AP-4, BHLHE40, GATA,GR, Irf, Pax-5 WBSCR22, 
MLXIPL 
FZD9 
7q11.23 RHBDD2, POR 
STYXL1, 
TMEM120A, MDH2, 
HSPB1 
rs17685, A      Arnt, BHLHE40, DEC,Ets, Mxi1,Myc, 
Pax-5, Sin3Ak-20, TFE 
RHBDD2, 
POR, 
TMEM120A, 
STYXL1, 
MDH2 
STYXL1 
11p13 CCDC34, LIN7C, 
METTL15, 
rs6265, C Val66Met    promoter 
enhancer 
BHLHE40, Myc, SREBP   
15q24 PPCDC, ARID3B, 
ULK3, SEMA7A, 
EDC3, COX5A, 
CSK, RPP25, MPI 
rs2470893, T 
rs2472297, T 
     SP1 MPI, SCAMP2, 
ULK3, ISLR, 
SNUPN, 
RPP25,CSK, 
SCAMP2 
17q11.2 TAOK1, SLC6A4 
NSRP1,  
BLMH 
rs9902453, G     promoter 
enhancer 
STAT GIT1, ATAD5, 
SLC6A4 
NSRP1,  
ANKRD13B, 
CRLF3, 
CORO6 
Abbreviations: CR, conserved region; eQTL, expression quantitative trait loci; mQTL, methylation quantitative trait loci 
aSee Supplementary Information for details and references to data resources.  
bIn vitro human hepatic gene expression in response to caffeine. Red and green font corresponds to increased and decreased expression, respectively.  
cLead SNP-allele associated with higher coffee consumption. 
Check marks () denote presence of  
dnon-synonymous SNPs in LD (CEU: r2≥0.80) with lead SNP (details provided for lead SNP only). 
ea conserved region (spanning lead SNP and its correlated proxies, CEU: r2≥0.8). 
fDNAse hypersensitivity sites at region spanning lead SNP and its correlated proxies, CEU: r2≥0.8. 
 gproteins bound at region spanning lead SNP and its correlated proxies, CEU: r2≥0.8. 
hEnhancer (H3K4me1) or promoter (H3K4me3) histone marks (as defined by Ernst et al32) spanning lead SNP and its correlated proxies, CEU: r2≥0.8.  
iRegulatory motifs altered by lead SNP.  
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jExpression QTLs for lead SNP or perfect proxy (CEU: r2=1) derived from lymphoblastoid cell lines, blood, or liver, adipose and brain tissues. Red and green font corresponds to 
increased and decreased expression, respectively, relative to allele associated with higher coffee consumption. Direction of GITI expression is not available. 
kMethylation QTLs for lead SNP derived from cerebellum and frontal cortex. Red and green font corresponds to increased and decreased expression, respectively, relative to allele 
associated with higher coffee consumption.
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Table 3. Associations between coffee consumption loci and other traits  
Lead SNP,  
allele ↑ coffee  
consumptiona  
closest gene 
Other Traitsb 
higher levels/riskc lower levels/riskc 
rs1260326, C 
GCKR 
non-albumin protein 
fasting glucose 
HOMA-IR 
fasting insulin 
mannose 
 
serum albumin 
2-hr glucose challenge 
metabolic syndrome 
glucose/mannose ratio 
total cholesterol 
triglycerides 
hypertriglyceridemia 
chronic kidney disease 
uric acid 
SHBG 
Crohn’s disease 
C-reactive protein 
platelet counts 
GGT 
docosapentaenoic acid 
alanine/glutamine ratio 
alanine 
 LDL (P=2.33×10-4) 
waist-to-hip-ratio (P=3.40×10-4) 
bipolar disorder (P=2.31×10-3) 
rs1481012, A 
ABCG2 
 LDL response to statins (‘responders’) 
uric acid 
body mass index (P=4.85×10-3)  
rs6968554 , G  
AHR 
 caffeine 
 HDL (P=1.18×10-3) 
rs7800944, C 
MLXIPL 
 triglycerides 
HDL (P=2.24×10-3) 
birth weight (P=2.10×10-3) 
 
rs6265, C 
BDNF 
smoking initiation 
body mass index 
 
 DBP (P=6.58×10-4) 
rs2472297d, T 
CYP1A1_CYP1A2 
 caffeinee 
 SBP (P=6.81×10-5) 
DBP (P=6.75×10-6) 
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rs9902453, G 
EFCAB5 
 SBP (P=6.05×10-3) 
Abbreviations: DBP, diastolic blood pressure; GGT, gamma-glutamyltransferase; HDL, high density lipoprotein; 
LDL, low density lipoprotein; SBP, systolic blood pressure; SHBG, sex hormone binding globulin 
aLead SNP-allele associated with higher coffee consumption. 
bTraits associated with lead SNP (or close proxies: r2>0.80) according to previous GWAS20(Shin et al, 2014). Grey 
cells denote all GW-significant significant associations (P<5.00 ×10-8  20 or  P<1.03 ×10-10 (Shin et al, 2014) and 
white cells denote coffee-relevant trait associations (P<6.25×10-3). See Supplementary Information for details and 
references to original GWAS.  
cRelative to allele associated with higher coffee consumption.   
drs1378942 A, also associated with higher coffee consumption (P<1.46×10-17) in stage 1 of the current report but in 
low LD with rs2472297 (CEU: r2=0.10), was previously associated with lower DBP in GWAS (P<5.00×10-8). 
eBorderline significant (P<1.51 ×10-10)  according to Shin et al 21. 
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Figure 1. Network describing direct interactions between candidate genes of confirmed loci. 
 
  
 
